Last Posted: Jan 25, 2019
- CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial.
Smith D Max et al. Genetics in medicine : official journal of the American College of Medical Genetics 2019 Jan - Pain polymorphisms and opioids: An evidence based review.
Vieira Cláudia Margarida Pereira et al. Molecular medicine reports 2018 Dec - Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients.
Muriel Javier et al. Basic & clinical pharmacology & toxicology 2018 Oct - [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine].
Kibitov ? ? et al. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 116(11. Vyp. 2) 36-48 - CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort.
Dagostino Concetta et al. Pharmacogenomics and personalized medicine 2018 11179-191 - Predicting those at risk for opioid abuse
M McFadden, November 1,2018 - Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis.
Blum Kenneth et al. Biomedical journal of scientific & technical research 2018 Jan 2(2) 1-4 - Gutted about opioids- The microbiome may have an influence on addiction
W Yan, Nature Medicine, October 30, 2018 - PharmGKB oxycodone pathway published in Pharmacogenetics and Genomics
PHRMGKB, October 2018 - Avoidable drug-gene conflicts and polypharmacy interactions in patients participating in a personalized medicine program.
Reynolds Kristen K et al. Personalized medicine 2017 14(3) 221-233
.png)
No hay comentarios:
Publicar un comentario